Glucose-6-Phosphate Dehydrogenase Deficiency, Chlorproguanil-Dapsone with Artesunate and Post-treatment Haemolysis in African children treated for uncomplicated Malaria
Authors
Van Malderen, CarineVan Geertruyden, Jean-Pierre
Machevo, Sonia
González, Raquel
Bassat, Quique
Talisuna, Ambrose
Yeka, Adoke
Nabasumba, Carolyn
Piola, Patrice
Daniel, Atwine
Turyakira, Eleanor
Forret, Pascale
Van Overmeir, Chantal
van Loen, Harry
Robert, Annie
D' Alessandro, Umberto
Affiliation
Faculté de pharmacie et des sciences biomédicales, Université catholique de Louvain, Brussels, Belgium. carine.vanmalderen@uclouvain.beIssue Date
2012-04-30
Metadata
Show full item recordJournal
Malaria JournalAbstract
Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy (ACT), but its development was prematurely stopped because of safety concerns secondary to its associated risk of haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The objective of the study was to assess whether CDA treatment and G6PD deficiency are risk factors for a post-treatment haemoglobin drop in African children<5 years of age with uncomplicated malaria.PubMed ID
22546009Language
enISSN
1475-2875ae974a485f413a2113503eed53cd6c53
10.1186/1475-2875-11-139
Scopus Count
Collections
Related articles
- Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials.
- Authors: Carter N, Pamba A, Duparc S, Waitumbi JN
- Issue date: 2011 Aug 17
- High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency.
- Authors: Fanello CI, Karema C, Avellino P, Bancone G, Uwimana A, Lee SJ, d'Alessandro U, Modiano D
- Issue date: 2008
- Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia.
- Authors: Dunyo S, Sirugo G, Sesay S, Bisseye C, Njie F, Adiamoh M, Nwakanma D, Diatta M, Janha R, Sisay Joof F, Temple B, Snell P, Conway D, Walton R, Cheung YB, Milligan P
- Issue date: 2011
- Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants.
- Authors: Poirot E, Vittinghoff E, Ishengoma D, Alifrangis M, Carneiro I, Hashim R, Baraka V, Mosha J, Gesase S, Chandramohan D, Gosling R
- Issue date: 2015
- Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria.
- Authors: Tiono AB, Dicko A, Ndububa DA, Agbenyega T, Pitmang S, Awobusuyi J, Pamba A, Duparc S, Goh LE, Harrell E, Carter N, Ward SA, Greenwood B, Winstanley PA
- Issue date: 2009 Dec